Who are Medicure Inc.'s main suppliers?

Medicure Inc. (MCUJF) key suppliers include: MEDICURE-INTERNATIONAL-INC, MEDICURE-PHARMA-INC, VIAL-AND-BAG-MANUFACTURERS, Merck & Co., Inc., Merck & Co., Inc.. View the full supplier network at chainsifter.com/chain/MCUJF.

Who are Medicure Inc.'s major customers?

Medicure Inc. (MCUJF) key customers include: MEDICARE-PART-D-COMPANY, Merck & Co., Inc., Merck & Co., Inc., CHIESI-FARMACEUTICS-S-P-A-INC, C-ORGANIZATIONAL-STRUCTURE-MEDICURE-INTERNATIONA and 3 more. View the full customer network at chainsifter.com/chain/MCUJF.

What sector is Medicure Inc. in?

Medicure Inc. (MCUJF) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Medicure Inc. Suppliers, Customers & Supply Chain (MCUJF)

5Suppliers

8Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Medicure Inc. (MCUJF) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

14Total relationships

2Distinct source URLs

5High confidence

0.738Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Medicure Inc. Suppliers

Ticker	Name	Confidence	Evidence
MEDICURE-INTERNATIONAL-INC	MEDICURE-INTERNATIONAL-INC	90%	The Company’s subsidiary, Medicure International, Inc., has a supply contract for raw materials (active pharmaceutical ingredient) used in the manufacture of AGGRASTAT ® with a contract manufacturer …
MEDICURE-PHARMA-INC	MEDICURE-PHARMA-INC	90%	The Company’s subsidiary, Medicure Pharma, Inc., has entered into a supply arrangement with a third-party manufacturer of ZYPITAMAG ® which will expire on September 19, 2029.
VIAL-AND-BAG-MANUFACTURERS	VIAL-AND-BAG-MANUFACTURERS	80%	The Company’s subsidiary, Medicure Pharma, Inc., has both vial and bag manufacturers of final product that are approved by the FDA.
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from MCUJF graph: Reciprocal relationship from MRK graph: Reciprocal relationship from MCUJF graph: o the Company and its business can …
MRK	Merck & Co., Inc.	72%	o the Company and its business can be found in the “Risk Factors” section of this Annual Report. 3 Table of Contents PART I ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS A. Directors …

Medicure Inc. Customers

Ticker	Name	Confidence	Evidence
MEDICARE-PART-D-COMPANY	MEDICARE-PART-D-COMPANY	85%	be attributed to a decrease in utilization of the product through insurance formularies, specifically Medicare Part D. Company’s retail pharmacy operating segment, Marley Drug, Gateway Pharmacy and W…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from MCUJF graph: Reciprocal relationship from MRK graph: Reciprocal relationship from MCUJF graph: Reciprocal relationship from MRK gr…
MRK	Merck & Co., Inc.	72%	ces performed by the Company’s customers, including the amount of such payment; · the Federal False Claims Act, which imposes civil and criminal liability on individuals and entities who submit, or c…
CHIESI-FARMACEUTICS-S-P-A-INC	CHIESI-FARMACEUTICS-S-P-A-INC	62%	ces performed by the Company’s customers, including the amount of such payment; · the Federal False Claims Act, which imposes civil and criminal liability on individuals and entities who submit, or c…
C-ORGANIZATIONAL-STRUCTURE-MEDICURE-INTERNATIONA	C-ORGANIZATIONAL-STRUCTURE-MEDICURE-INTERNATIONA	62%	ug) to the Company during the year ended December 31, 2024. Maintaining AGGRASTAT ® sales in the United States The Company continues to work to maintain the sales of AGGRASTAT ® in the United States.…
GATEWAY-PHARMACY-INC	GATEWAY-PHARMACY-INC	62%	escription of the matter On March 11, 2025 and June 16, 2025, the Company completed its acquisitions of Gateway Pharmacy Inc. (“Gateway”) and West Olympia Pharmacy, LLC (“West Olympia”) respectively …
HOUSE-WHITE-PARK-ROAD-BRIDGETOWN-BARBADOS-MEDICU	HOUSE-WHITE-PARK-ROAD-BRIDGETOWN-BARBADOS-MEDICU	62%	ug) to the Company during the year ended December 31, 2024. Maintaining AGGRASTAT ® sales in the United States The Company continues to work to maintain the sales of AGGRASTAT ® in the United States.…
LIMEGROVE-CENTRE-HOLETOWN-ST-JAMES-BARBADOS-MEDI	LIMEGROVE-CENTRE-HOLETOWN-ST-JAMES-BARBADOS-MEDI	62%	ug) to the Company during the year ended December 31, 2024. Maintaining AGGRASTAT ® sales in the United States The Company continues to work to maintain the sales of AGGRASTAT ® in the United States.…

Medicure Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
MCUJF-DEBT	Debt stack $582,094	90%	Market cache reports total debt of $582,094.

Medicure Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Medicure Inc..

Medicure Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for Medicure Inc..

Medicure Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
IBRX	ImmunityBio, Inc.	100.00	2
MRK	Merck & Co., Inc.	100.00	1	['customer', 'supplier']
ENLV	Enlivex Ltd.	100.00	2
HOWL	Werewolf Therapeutics, Inc.	100.00	2
IBIO	iBio, Inc.	100.00	2
STKH	Steakholder Foods Ltd.	100.00	2
EVAX	Evaxion A/S	100.00	2
BMY	Bristol-Myers Squibb Company	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
PSNL	Personalis, Inc.	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
TBPH	Theravance Biopharma, Inc.	100.00	2
MGNX	MacroGenics, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
ADAG	Adagene Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
IMMP	Immutep Limited	100.00	2
MRNA	Moderna, Inc.	100.00	2

Medicure Inc. Supply Chain